Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

Identification and characterization of CRG-L2, a new marker for liver tumor development

Oncogene volume 22, pages 1730–1736 (2003)Cite this article

Abstract

Liver cancer is very common worldwide and the rates of hepatocellular carcinoma (HCC) have increased by over 70% in the last 2 decades in the US. Late diagnosis, because of the lack of clinical symptoms, and decreased hepatic function, because of underlying hepatic disease, lead to the extremely high mortality rates associated with HCC. Clearly, the identification of markers that are expressed early in the development of HCC and that are easily detected in high-risk patients would aid in early diagnosis and increased survival. We present the cloning and characterization of a novel gene, CRG-L2 (Cancer related gene-Liver 2), which displays high expression in murine and human hepatocellular carcinomas. Using in situ hybridization, we show that CRG-L2 mRNA levels are increased early during the development of liver tumors in C3H/HeJ mice, and that in normal tissues CRG-L2 mRNA is restricted to the murine testis and human placenta. Its restricted expression in normal tissues and unique early upregulation during tumor development make CRG-L2 an excellent candidate as a new clinical marker of HCC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • American Cancer Society. (2002). Cancer Facts Figures, 1–44.

  • Borscheri N, Roessner A and Roecken C . (2001). Am. J. Surg. Pathol., 25, 1297–1303.

  • Bosch FX, Ribes J and Borras J . (1999). Semin. Liver Dis., 19, 271–285.

  • Brinkman U, Vasmatzis G, Lee B, Yerushalmi N, Essand M and Pastan I . (1998). Proc. Natl. Acac. Sci. USA, 95, 10757–10762.

  • El-Serag HB and Mason AC . (1999). N. Engl. J. Med., 340, 745–750.

  • Gilboa E . (1999). Immunity, 11, 263–270.

  • Graveel CR, Jatkoe T, Madore SJ, Holt AL and Farnham PJ . (2001). Oncogene, 20, 2704–2712.

  • Hanigan MH, Kemp CJ, Ginsler JJ and Drinkwater NR . (1988). Carcinogenesis, 9, 885–890.

  • Koen H, Pugh TD, Nychka D and Goldfarb S . (1983). Cancer Res., 43, 702–708.

  • Kulkarni N, Karavanich CA, Atchley WR and Anholt RRH . (2000). Genet. Res., 76, 41–50.

  • Lukas ER, Bartley SM, Graveel CR, Diaz ZM, Dyson N, Harlow E, Yamasaki L and Farnham PJ . (1999). Mol. Carcino., 25, 295–303.

  • Micales BK and Lyons GE . (2001). Methods, 23, 313–323.

  • Moore MR, Drinkwater NR, Miller EC, Miller JA and Pilot HC . (1981). Cancer Res., 41, 1585–1593.

  • Ono T, Kurashige T, Harada N, Noguchi Y, Saika T, Niikawa N, Aoc M, Nakamura S, Higashi T, Hiraki A, Wada H, Kumon H, Old L and Nakayama E . (2001). Proc. Natl. Acad. Sci. USA, 98, 3282–3287.

  • Rainov NG, Dobberstein KU, Fittkau M Bahn H, Holzhausen HJ, Gantchev L and Burkert W . (1995). Clin. Cancer Res., 1, 775–781.

  • Richards JE, Ritch R, Lichter PR, Rozsa FW, Stringham HM, Caronia RM, Johnson D, Abundo GP, Willcockson J, Downs CA, Thompson DA, Musarella MA, Gupta N, Othman MI, Torrez DM, Herman SB, Wong DJ, Higashi M and Boehnke M . (1998). Opthalmology, 105, 1698–1707.

  • Rigby PWJ, Dieekmann M, Rhoades C and Berg P . (1977) J. Mol. Biol., 113, 237–251.

  • Scanlan MJ, Altorki NK, Gure AO, Williamson B, Jungbluth A, Chen YT and Old LJ, (2000). Cancer Lett., 150, 155–164.

  • Scanlan MJ, Gordon CM, Williamson B, Lee S-Y, Chen Y-T, Stockert E ., Jungbluth A, Ritter G, Jäger D, Jäger E, Knuth A and Old LJ . (2002). Int. J. Cancer, 98, 485–492.

  • Song B, Chung C, Kim JA, Choi W, Suh DD, Pyo S, Shin JW, Lee HC, Lee YS and Suh DJ . (2002). Cancer, 94, 175–180.

  • Struss AK, Romeike BF, Munnia A, Steudel WI, Konig J, Ohgaki H, Feiden W, Fischer U and Meese E . (2001). Oncogene, 20, 4170–4174.

  • Türeci O, Sahin U, Zwick C, Koslowski M, Seitz G and Pfreundschuh M . (1998). Proc. Natl. Acad. Sci. USA, 95, 5211–5216.

  • Vesselinoviteh SD, Hacker HJ and Bannasch P . (1985). Cancer Res., 45, 2774–2780.

  • Zhang J, Liu W-L, Tang DC, Chen L, Wang M, Pack SD, Zhuang Z and Rodgers GP (2002). Gene, 283, 83–93.

Download references

Acknowledgements

We thank RK Hyde, S Moran, and C Sattler for technical assistance; J Ross for his generous gift of reagents; S Perry for the hydrophobicity analysis, the R Burgess lab, especially N Thompson, for their assistance with protein expression, and the Farnham lab for critical review of the manuscript. This work was supported in part by research grants from the National Cancer Institute/National Institutes of Health CA22484, National Institute of General Medical Sciences/National Institutes of Health GM08349, and National Cancer Institute/National Institutes of Health CA14520.

Author information

Authors and Affiliations

  1. McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI 53706, USA

    Carrie R Graveel, Sarah R Harkins-Perry, Luis G Acevedo & Peggy J Farnham

Authors
  1. Carrie R Graveel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah R Harkins-Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luis G Acevedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peggy J Farnham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peggy J Farnham.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Graveel, C., Harkins-Perry, S., Acevedo, L. et al. Identification and characterization of CRG-L2, a new marker for liver tumor development. Oncogene 22, 1730–1736 (2003). https://doi.org/10.1038/sj.onc.1206309

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206309

Keywords

This article is cited by

Search

Advanced search

Quick links